<DOC>
	<DOC>NCT02581592</DOC>
	<brief_summary>This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of TD-4208.</brief_summary>
	<brief_title>Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>For hepatic impairment group: Subject has moderate hepatic impairment (Child Pugh B) For normal hepatic function group: Subject is in good health Women who are pregnant, lactating, breastfeeding, or planning to become pregnant during the study. Subject has received an investigational drug (or medical device) within 30 days Subject who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition that would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Liver Cirrhosis</keyword>
</DOC>